[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345358-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345358-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","druggable-genome-wide-mendelian-randomization-identifies-therapeutic-targets-and-dna-methylation-mediated-regulation-in-urological-malignancies","Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies","","Multi-omics Mendelian randomization was used to systematically identify druggable therapeutic targets in urological cancers and to clarify DNA methylation-mediated regulatory mechanisms. Transcriptome-wide MR employed cis-eQTL exposure data from eQTLGen (N=31,684) and GWAS outcomes from FinnGen R11 and Open GWAS, followed by Bonferroni filtering, colocalization, and SMR. Drug prediction and molecular docking validated candidates, while mediation MR integrated GoDMC mQTL to reveal methylation–gene expression axes. Eleven targets were prioritized, supported by docking and epigenetic evidence, including PROC, CELSR1, and SIK2.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/druggable-genome-wide-mendelian-randomization-identifies-therapeutic-targets-and-dna-methylation-mediated-regulation-in-urological-malignancies/345358/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/druggable-genome-wide-mendelian-randomization-identifies-therapeutic-targets-and-dna-methylation-mediated-regulation-in-urological-malignancies/345358.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary goal of this study in urological cancers?","Question",{"text":63,"@type":64},"To systematically identify new therapeutic targets by integrating multi-omics data and to elucidate the molecular mechanisms, specifically DNA methylation-mediated regulation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and analyses were used to discover therapeutic targets?",{"text":68,"@type":64},"Cis-eQTL data from eQTLGen (as exposures) and GWAS summary statistics from FinnGen R11 and Open GWAS (as outcomes) were analyzed using transcriptome-wide Mendelian randomization, with Bonferroni correction, colocalization, and SMR.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the study validate the identified therapeutic targets?",{"text":72,"@type":64},"Validation included drug prediction using DSigDB and molecular docking with AutoDock Vina, followed by epigenetic mediation analysis using GoDMC mQTL data to assess methylation-driven regulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345358,1790378063,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies  \nTaoen Li1  and Qiang Wei1,2  \nAbstract  \nTechnology in Cancer Research & Treatment Volume 25: 1–26 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/15330338261449014](DOI: 10.1177/15330338261449014)  \n[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nIntroduction: Urological cancers, including prostate, renal, and bladder cancers, present significant challengesto human health, particularly for patients in advanced stages due to limited targeted therapy options, high drug resistance, and poor prognosis. This study seeks to systematically identify new therapeutic targets by integrating multi-omics data and elucidating their molecular mechanisms. Methods: Our methodology involved a multi-phase integrative approach to identify therapeutic targets in urological cancers. We conducted a transcriptome-wide Mendelian randomization (TWMR) analysis using the druggable genome. We used cis-expression quantitative trait loci (cis-eQTL) data from theeQTLGen consortium (N = 31,684) as exposuresand GWAS summary statistics from FinnGen R11 and Open GWAS as outcomes. Significant genes were identified through Bonferroni correction, followed by colocalization analysis to assess shared genetic effects between riskSNPsand gene expression. Summary-data-based MR (SMR) analysis was carried out using eQTLGen data. Validation of potential targets included drug prediction using DSigDB and molecular docking with AutoDock Vina. Furthermore, we integrated DNA methylation quantitative trait loci (mQTL) data from GoDMC to explore methylation-mediated regulatory mechanisms through mediation MR analysis. Results: Our transcriptomewide MR analysis identified 11 high-confidence therapeutic targets in urological cancers: 4 in prostate cancer (BNIP2, KAT5, MMP24, SIK2), 2 in renal cancer (GRB10, GPR17), and 5 in bladder cancer (CELSR1, GPS1, PROC, GSTM1, KLC3). Molecular docking confirmed favorable interactions between these targets and existing drugs. Epigenetic analyses showed DNA methylationmediated regulation of key targets: PROC (cg09747827) and CELSR1 (cg00784671) in bladder cancer, and SIK2 (cg11344533) in prostate cancer. Conclusions: This study integrates multi-omics data to identify 11 high-confidence therapeutic targets inurological cancers and is the first to elucidate DNA methylation-mediated regulatory mechanisms for targets like PROC and SIK2. The findings introduce a “DNA methylation-gene expression” axis-based strategy for combined targeted-epigenetic therapy, providing crucial evidence for optimizing precision treatment in urological oncology.  \nKeywords  \ndruggable genome, Mendelian randomization (MR), DNA methylation, urological cancers, therapeutic targets, multi-omics analysis  \nReceived: 3 November 2025; Revised: 8 April 2026; Accepted: 22 April 2026  \n1Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China  \n2Department of Urology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510080, China  \nCorresponding author:  \nQiang Wei, Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China; Department of Urology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, 510080, China.  \nEmail: [qwei@smu.edu.cn](qwei@smu.edu.cn)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which perm","cbCaiePAtwf5X92L","https://ap.wps.com/l/cbCaiePAtwf5X92L","pdf",5533133,26,"English","# Introduction\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What was the primary goal of this study in urological cancers?\",\"answer\":\"To systematically identify new therapeutic targets by integrating multi-omics data and to elucidate the molecular mechanisms, specifically DNA methylation-mediated regulation.\"},{\"question\":\"Which datasets and analyses were used to discover therapeutic targets?\",\"answer\":\"Cis-eQTL data from eQTLGen (as exposures) and GWAS summary statistics from FinnGen R11 and Open GWAS (as outcomes) were analyzed using transcriptome-wide Mendelian randomization, with Bonferroni correction, colocalization, and SMR.\"},{\"question\":\"How did the study validate the identified therapeutic targets?\",\"answer\":\"Validation included drug prediction using DSigDB and molecular docking with AutoDock Vina, followed by epigenetic mediation analysis using GoDMC mQTL data to assess methylation-driven regulation.\"}]","Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies | PDF",1790057431,66,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0816a2429b511ab3e884a2bbcae21ca.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81ac843708d603a133dbbafbd80a21a2.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4237177f7a89af5f829d45978d43bc0.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/803488e1389a007729e2cdb87af51a2b.webp",980,1306]